bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 5 from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
Authors: Sarker Debashis , Plummer Ruth , Meyer Tim , Sodergren Mikael H. , Basu Bristi , Chee Cheng Ean , Huang Kai-Wen , Palmer Daniel H. , Ma Yuk Ting , Evans T.R. Jeff , Spalding Duncan R.C. , Pai Madhava , Sharma Rohini , Pinato David J. , Spicer James , Hunter Sarah , Kwatra Vineet , Nicholls Joanna P. , Collin David , Nutbrown Robert , Glenny Helen , Fairbairn Sonia , Reebye Vikash , Voutila Jon , Dorman Stephanie , Andrikakou Pinelopi , Lloyd Peter , Felstead Steve , Vasara Jenni , Habib Robert , Wood Chris , Saetrom Pal , Huber Hans E. , Blakey David C. , Rossi John J. , Habib Nagy
Published: April 2023

Showing complete radiological response of lung metastases
Supplementary Figure 4 from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
Authors: Sarker Debashis , Plummer Ruth , Meyer Tim , Sodergren Mikael H. , Basu Bristi , Chee Cheng Ean , Huang Kai-Wen , Palmer Daniel H. , Ma Yuk Ting , Evans T.R. Jeff , Spalding Duncan R.C. , Pai Madhava , Sharma Rohini , Pinato David J. , Spicer James , Hunter Sarah , Kwatra Vineet , Nicholls Joanna P. , Collin David , Nutbrown Robert , Glenny Helen , Fairbairn Sonia , Reebye Vikash , Voutila Jon , Dorman Stephanie , Andrikakou Pinelopi , Lloyd Peter , Felstead Steve , Vasara Jenni , Habib Robert , Wood Chris , Saetrom Pal , Huber Hans E. , Blakey David C. , Rossi John J. , Habib Nagy
Published: April 2023

A) CT and MRI of patient with prolonged partial response with MTL-CEBPA treatment B) IFN-gamma, NFkB and IL6 trend at days 1, 8 and 15 following treatment and C) AFP change at from baseline to 4, 8 and 16 weeks on treatment
Supplementary table S1 from Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma
Authors: Meel Michaël H. , de Gooijer Mark C. , Metselaar Dennis S. , Sewing A. Charlotte P. , Zwaan Kenn , Waranecki Piotr , Breur Marjolein , Buil Levi C.M. , Lagerweij Tonny , Wedekind Laurine E. , Twisk Jos W.R. , Koster Jan , Hashizume Rintaro , Raabe Eric H. , Montero Carcaboso Ángel , Bugiani Marianna , Phoenix Timothy N. , van Tellingen Olaf , van Vuurden Dannis G. , Kaspers Gertjan J.L. , Hulleman Esther
Published: April 2023

Sequences of shRNA constructs used in the present study.
Supplementary Figure 1 from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
Authors: Sarker Debashis , Plummer Ruth , Meyer Tim , Sodergren Mikael H. , Basu Bristi , Chee Cheng Ean , Huang Kai-Wen , Palmer Daniel H. , Ma Yuk Ting , Evans T.R. Jeff , Spalding Duncan R.C. , Pai Madhava , Sharma Rohini , Pinato David J. , Spicer James , Hunter Sarah , Kwatra Vineet , Nicholls Joanna P. , Collin David , Nutbrown Robert , Glenny Helen , Fairbairn Sonia , Reebye Vikash , Voutila Jon , Dorman Stephanie , Andrikakou Pinelopi , Lloyd Peter , Felstead Steve , Vasara Jenni , Habib Robert , Wood Chris , Saetrom Pal , Huber Hans E. , Blakey David C. , Rossi John J. , Habib Nagy
Published: April 2023

Dose escalation flow chart. DLT - dose limiting toxicity, MTD - maximum tolerated dose
Supplementary Data from Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer
Authors: Malihi Paymaneh D. , Graf Ryon P. , Rodriguez Angel , Ramesh Naveen , Lee Jerry , Sutton Ramsay , Jiles Rhett , Ruiz Velasco Carmen , Sei Emi , Kolatkar Anand , Logothetis Christopher , Navin Nicholas E. , Corn Paul , Aparicio Ana M. , Dittamore Ryan , Hicks James , Kuhn Peter , Zurita Amado J.
Published: April 2023

Figures and Tables
Figure S6 from A Radiomics Model for Predicting the Response to Bevacizumab in Brain Necrosis after Radiotherapy
Authors: Cai Jinhua , Zheng Junjiong , Shen Jun , Yuan Zhiyong , Xie Mingwei , Gao Miaomiao , Tan Hongqi , Liang Zhongguo , Rong Xiaoming , Li Yi , Li Honghong , Jiang Jingru , Zhao Huiying , Argyriou Andreas A. , Chua Melvin L.K. , Tang Yamei
Published: April 2023

Figure S6. Clinical usefulness of the radiomics model.
Figure S4 from A Radiomics Model for Predicting the Response to Bevacizumab in Brain Necrosis after Radiotherapy
Authors: Cai Jinhua , Zheng Junjiong , Shen Jun , Yuan Zhiyong , Xie Mingwei , Gao Miaomiao , Tan Hongqi , Liang Zhongguo , Rong Xiaoming , Li Yi , Li Honghong , Jiang Jingru , Zhao Huiying , Argyriou Andreas A. , Chua Melvin L.K. , Tang Yamei
Published: April 2023

Figure S4. Histogram showing the coefficients of the selected features in the radiomics signature.
Figure S3 from A Radiomics Model for Predicting the Response to Bevacizumab in Brain Necrosis after Radiotherapy
Authors: Cai Jinhua , Zheng Junjiong , Shen Jun , Yuan Zhiyong , Xie Mingwei , Gao Miaomiao , Tan Hongqi , Liang Zhongguo , Rong Xiaoming , Li Yi , Li Honghong , Jiang Jingru , Zhao Huiying , Argyriou Andreas A. , Chua Melvin L.K. , Tang Yamei
Published: April 2023

Figure S3. Selection of radiomics features using LASSO logistic regression.
Figure S2 from A Radiomics Model for Predicting the Response to Bevacizumab in Brain Necrosis after Radiotherapy
Authors: Cai Jinhua , Zheng Junjiong , Shen Jun , Yuan Zhiyong , Xie Mingwei , Gao Miaomiao , Tan Hongqi , Liang Zhongguo , Rong Xiaoming , Li Yi , Li Honghong , Jiang Jingru , Zhao Huiying , Argyriou Andreas A. , Chua Melvin L.K. , Tang Yamei
Published: April 2023

Figure S2. Representative images of patients with bilateral brain lesions.
Supplementary Table S8 from Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non–Small Cell Lung Cancer
Authors: Liu Bin , Ricarte Filho Julio , Mallisetty Apurva , Villani Cassandra , Kottorou Anastasia , Rodgers Kristen , Chen Chen , Ito Tomoaki , Holmes Kyla , Gastala Nicole , Valyi-Nagy Klara , David Odile , Gaba Ron C. , Ascoli Christian , Pasquinelli Mary , Feldman Lawrence E. , Massad Malek G. , Wang Tza-Huei , Jusue-Torres Ignacio , Benedetti Enrico , Winn Robert A. , Brock Malcolm V. , Herman James G. , Hulbert Alicia
Published: April 2023

Gene Methylation Detection, Sensitivity, Specificity Using Detectable vs. Non-detectable cutoff in whites
Figure S4 from Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to Immunotherapy
Authors: Klein Sebastian , Quaas Alexander , Noh Ka-Won , Cartolano Maria , Abedpour Nima , Mauch Cornelia , Quantius Jennifer , Reinhardt Hans Christian , Buettner Reinhard , Peifer Martin , Helbig Doris
Published: April 2023

Figure S4
Figure S1 from Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to Immunotherapy
Authors: Klein Sebastian , Quaas Alexander , Noh Ka-Won , Cartolano Maria , Abedpour Nima , Mauch Cornelia , Quantius Jennifer , Reinhardt Hans Christian , Buettner Reinhard , Peifer Martin , Helbig Doris
Published: April 2023

Figure S1
Supplementary Table S3 from Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non–Small Cell Lung Cancer
Authors: Liu Bin , Ricarte Filho Julio , Mallisetty Apurva , Villani Cassandra , Kottorou Anastasia , Rodgers Kristen , Chen Chen , Ito Tomoaki , Holmes Kyla , Gastala Nicole , Valyi-Nagy Klara , David Odile , Gaba Ron C. , Ascoli Christian , Pasquinelli Mary , Feldman Lawrence E. , Massad Malek G. , Wang Tza-Huei , Jusue-Torres Ignacio , Benedetti Enrico , Winn Robert A. , Brock Malcolm V. , Herman James G. , Hulbert Alicia
Published: April 2023

Correlation of Î"Ct methylation between Plasma and Urine
Figure S4 from Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non–Small Cell Lung Cancer
Authors: Liu Bin , Ricarte Filho Julio , Mallisetty Apurva , Villani Cassandra , Kottorou Anastasia , Rodgers Kristen , Chen Chen , Ito Tomoaki , Holmes Kyla , Gastala Nicole , Valyi-Nagy Klara , David Odile , Gaba Ron C. , Ascoli Christian , Pasquinelli Mary , Feldman Lawrence E. , Massad Malek G. , Wang Tza-Huei , Jusue-Torres Ignacio , Benedetti Enrico , Winn Robert A. , Brock Malcolm V. , Herman James G. , Hulbert Alicia
Published: April 2023

Figure S4
Supplementary Data from CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
Authors: Leuci Valeria , Donini Chiara , Grignani Giovanni , Rotolo Ramona , Mesiano Giulia , Fiorino Erika , Gammaitoni Loretta , D'Ambrosio Lorenzo , Merlini Alessandra , Landoni Elisa , Medico Enzo , Capellero Sonia , Giraudo Lidia , Cattaneo Giulia , Iaia Ilenia , Pignochino Ymera , Basiricò Marco , Vigna Elisa , Pisacane Alberto , Fagioli Franca , Ferrone Soldano , Aglietta Massimo , Dotti Gianpietro , Sangiolo Dario
Published: April 2023

Supplemental Table 2. Phenotypic characterization of STS cell lines
Supplementary Figure S7 from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma
Authors: Dai Wei , Chung Dittman Lai-Shun , Chow Larry Ka-Yue , Yu Valen Zhuoyou , Lei Lisa Chan , Leong Merrin Man-Long , Chan Candy King-Chi , Ko Josephine Mun-Yee , Lung Maria Li
Published: April 2023

Figure S7: Distinct host and EBV methylation in NPC cases with BRCAness signature. (A) Differential methylation between signature-positive and -negative cases measured by Illumina HumanMethylation450 array. (B) EBV methylation between signature-positive and -negative cases. Differential methylation was observed at two regions. (C) Differential methylation at EBV genome for two selected regions. (D) Ratios of LMP-1 and LMP-2A expression between signature-positive and -negative groups.
Supplementary Figure S6 from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma
Authors: Dai Wei , Chung Dittman Lai-Shun , Chow Larry Ka-Yue , Yu Valen Zhuoyou , Lei Lisa Chan , Leong Merrin Man-Long , Chan Candy King-Chi , Ko Josephine Mun-Yee , Lung Maria Li
Published: April 2023

Figure S6: Methylation of selected genes between signature 3-positive and -negative groups.
Supplemental Figure 5 from CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
Authors: Leuci Valeria , Donini Chiara , Grignani Giovanni , Rotolo Ramona , Mesiano Giulia , Fiorino Erika , Gammaitoni Loretta , D'Ambrosio Lorenzo , Merlini Alessandra , Landoni Elisa , Medico Enzo , Capellero Sonia , Giraudo Lidia , Cattaneo Giulia , Iaia Ilenia , Pignochino Ymera , Basiricò Marco , Vigna Elisa , Pisacane Alberto , Fagioli Franca , Ferrone Soldano , Aglietta Massimo , Dotti Gianpietro , Sangiolo Dario
Published: April 2023

CSPG4-CAR.CIK show antitumor activity in STS xenograft models
Supplementary Figure S5 from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma
Authors: Dai Wei , Chung Dittman Lai-Shun , Chow Larry Ka-Yue , Yu Valen Zhuoyou , Lei Lisa Chan , Leong Merrin Man-Long , Chan Candy King-Chi , Ko Josephine Mun-Yee , Lung Maria Li
Published: April 2023

Figure S5: Methylation of selected genes between NPC and adjacent non-tumor tissues.
Figure S4 from A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer
Authors: Prat Aleix , Tsai Yi-Hsuan , Pascual Tomás , Paré Laia , Adamo Barbara , Vidal Maria , Brasó-Maristany Fara , Galván Patricia , Brase Jan Christoph , Rodrik-Outmezguine Vanessa , Johnston Stephen , Ciruelos Eva , Parker Joel S.
Published: April 2023

PAM50MET score as a continuous predictor of probability of (A) progression-free survival and (B) overall survival in EGF30008 and (C) progression-free survival (D) and overall survival in BOLERO-2 (dashed lines as 95% CI). CI, confidence interval; PAM50MET, final model.
Figure S3 from A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer
Authors: Prat Aleix , Tsai Yi-Hsuan , Pascual Tomás , Paré Laia , Adamo Barbara , Vidal Maria , Brasó-Maristany Fara , Galván Patricia , Brase Jan Christoph , Rodrik-Outmezguine Vanessa , Johnston Stephen , Ciruelos Eva , Parker Joel S.
Published: April 2023

Survival outcomes based on the PAM50MET score in the BOLERO-2 trial. (A) Progression-free survival using a predefined cutoff in patients treated with placebo. (B) Progression-free survival using a predefined cutoff in patients treated with everolimus. (C) Overall survival using a predefined cutoff in patients treated with placebo. (D) Overall survival using a predefined cutoff in patients treated with everolimus. Interaction tests between PAM50 and treatment arm for PFS and OS were statistically non-significant (all p-values >0.05). PAM50MET, final model.
Table S1 from Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer
Authors: Crosby Erika J. , Acharya Chaitanya R. , Haddad Anthony-Fayez , Rabiola Christopher A. , Lei Gangjun , Wei Jun-Ping , Yang Xiao-Yi , Wang Tao , Liu Cong-Xiao , Wagner Kay U. , Muller William J. , Chodosh Lewis A. , Broadwater Gloria , Hyslop Terry , Shepherd Jonathan H. , Hollern Daniel P. , He Xiaping , Perou Charles M. , Chai Shengjie , Ashby Benjamin K. , Vincent Benjamin G. , Snyder Joshua C. , Force Jeremy , Morse Michael A. , Lyerly Herbert K. , Hartman Zachary C.
Published: April 2023

Supplementary Table 1
Supplementary Table S2 from Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
Authors: Facchinetti Francesco , Hollebecque Antoine , Bahleda Rastislav , Loriot Yohann , Olaussen Ken A. , Massard Christophe , Friboulet Luc
Published: April 2023

Activity and efficacy data of selective FGFR inhibitors in tumors other than urothelial cancers and cholangiocarcinomas.
Supplementary Data from Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials
Authors: Kates Max , Matoso Andres , Choi Woonyoung , Baras Alexander S. , Daniels Marcus J. , Lombardo Kara , Brant Aaron , Mikkilineni Nina , McConkey David J. , Kamat Ashish M. , Svatek Robert S. , Porten Sima P. , Meeks Joshua J. , Lerner Seth P. , Dinney Colin P. , Black Peter C. , McKiernan James M. , Anderson Chris , Drake Charles G. , Bivalacqua Trinity J.
Published: April 2023

Supplementary Figure 2
Figure S1 from Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer
Authors: Crosby Erika J. , Acharya Chaitanya R. , Haddad Anthony-Fayez , Rabiola Christopher A. , Lei Gangjun , Wei Jun-Ping , Yang Xiao-Yi , Wang Tao , Liu Cong-Xiao , Wagner Kay U. , Muller William J. , Chodosh Lewis A. , Broadwater Gloria , Hyslop Terry , Shepherd Jonathan H. , Hollern Daniel P. , He Xiaping , Perou Charles M. , Chai Shengjie , Ashby Benjamin K. , Vincent Benjamin G. , Snyder Joshua C. , Force Jeremy , Morse Michael A. , Lyerly Herbert K. , Hartman Zachary C.
Published: April 2023

Supplementary Figure 1
figure S5 from Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma
Authors: Marusak Charles , Thakur Varsha , Li Yuan , Freitas Juliano T. , Zmina Patrick M. , Thakur Vijay S. , Chang Mayland , Gao Ming , Tan Jiufeng , Xiao Min , Lu Yiling , Mills Gordon B. , Flaherty Keith , Frederick Dennie T. , Miao Benchun , Sullivan Ryan J. , Moll Tabea , Boland Genevieve M. , Herlyn Meenhard , Zhang Gao , Bedogni Barbara
Published: April 2023

cell growth
Supplementary Figure 7 from PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma
Authors: Ganci Federica , Pulito Claudio , Valsoni Sara , Sacconi Andrea , Turco Chiara , Vahabi Mahrou , Manciocco Valentina , Mazza Emilia Maria Cristina , Meens Jalna , Karamboulas Christina , Nichols Anthony C. , Covello Renato , Pellini Raul , Spriano Giuseppe , Sanguineti Giuseppe , Muti Paola , Bicciato Silvio , Ailles Laurie , Strano Sabrina , Fontemaggi Giulia , Blandino Giovanni
Published: April 2023

Supplementary Figure 7
Supplementary Figure 6 from PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma
Authors: Ganci Federica , Pulito Claudio , Valsoni Sara , Sacconi Andrea , Turco Chiara , Vahabi Mahrou , Manciocco Valentina , Mazza Emilia Maria Cristina , Meens Jalna , Karamboulas Christina , Nichols Anthony C. , Covello Renato , Pellini Raul , Spriano Giuseppe , Sanguineti Giuseppe , Muti Paola , Bicciato Silvio , Ailles Laurie , Strano Sabrina , Fontemaggi Giulia , Blandino Giovanni
Published: April 2023

Supplementary Figure 6
Figure S2 from Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma
Authors: Marusak Charles , Thakur Varsha , Li Yuan , Freitas Juliano T. , Zmina Patrick M. , Thakur Vijay S. , Chang Mayland , Gao Ming , Tan Jiufeng , Xiao Min , Lu Yiling , Mills Gordon B. , Flaherty Keith , Frederick Dennie T. , Miao Benchun , Sullivan Ryan J. , Moll Tabea , Boland Genevieve M. , Herlyn Meenhard , Zhang Gao , Bedogni Barbara
Published: April 2023

RPPA data
Supplementary Figure 5 from PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma
Authors: Ganci Federica , Pulito Claudio , Valsoni Sara , Sacconi Andrea , Turco Chiara , Vahabi Mahrou , Manciocco Valentina , Mazza Emilia Maria Cristina , Meens Jalna , Karamboulas Christina , Nichols Anthony C. , Covello Renato , Pellini Raul , Spriano Giuseppe , Sanguineti Giuseppe , Muti Paola , Bicciato Silvio , Ailles Laurie , Strano Sabrina , Fontemaggi Giulia , Blandino Giovanni
Published: April 2023

Supplementary Figure 5
Figure S10 from Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma
Authors: Marusak Charles , Thakur Varsha , Li Yuan , Freitas Juliano T. , Zmina Patrick M. , Thakur Vijay S. , Chang Mayland , Gao Ming , Tan Jiufeng , Xiao Min , Lu Yiling , Mills Gordon B. , Flaherty Keith , Frederick Dennie T. , Miao Benchun , Sullivan Ryan J. , Moll Tabea , Boland Genevieve M. , Herlyn Meenhard , Zhang Gao , Bedogni Barbara
Published: April 2023

degradable, non-degradable matrixes
Supplementary Figure 3 from PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma
Authors: Ganci Federica , Pulito Claudio , Valsoni Sara , Sacconi Andrea , Turco Chiara , Vahabi Mahrou , Manciocco Valentina , Mazza Emilia Maria Cristina , Meens Jalna , Karamboulas Christina , Nichols Anthony C. , Covello Renato , Pellini Raul , Spriano Giuseppe , Sanguineti Giuseppe , Muti Paola , Bicciato Silvio , Ailles Laurie , Strano Sabrina , Fontemaggi Giulia , Blandino Giovanni
Published: April 2023

Supplementary Figure 3
Figure S1 from Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma
Authors: Marusak Charles , Thakur Varsha , Li Yuan , Freitas Juliano T. , Zmina Patrick M. , Thakur Vijay S. , Chang Mayland , Gao Ming , Tan Jiufeng , Xiao Min , Lu Yiling , Mills Gordon B. , Flaherty Keith , Frederick Dennie T. , Miao Benchun , Sullivan Ryan J. , Moll Tabea , Boland Genevieve M. , Herlyn Meenhard , Zhang Gao , Bedogni Barbara
Published: April 2023

Patients samples
Supplementary Data from Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer
Authors: Adachi Yuta , Ito Kentaro , Hayashi Yuko , Kimura Ryo , Tan Tuan Zea , Yamaguchi Rui , Ebi Hiromichi
Published: April 2023

Supplementary Methods, Supplementary Table S1 to S4, and Supplementary Figure S1 to S4.
Table S5 from PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Authors: Guarneri Valentina , Dieci Maria Vittoria , Bisagni Giancarlo , Brandes Alba A. , Frassoldati Antonio , Cavanna Luigi , Musolino Antonino , Giotta Francesco , Rimanti Anita , Garrone Ornella , Bertone Elena , Cagossi Katia , Nanni Oriana , Piacentini Federico , Orvieto Enrico , Griguolo Gaia , Curtarello Matteo , Urso Loredana , Paré Laia , Chic Nuria , D'Amico Roberto , Prat Aleix , Conte Pierfranco
Published: April 2023

Additional prognostic value (DFS) of TILs, PIK3CA mutation, PDCD1 expression and MYBL2 expression to integrated prognostic models.
Supplementary Table S3A and S3B from Electronic DNA Analysis of CSF Cell-free Tumor DNA to Quantify Multi-gene Molecular Response in Pediatric High-grade Glioma
Authors: Bruzek Amy K. , Ravi Karthik , Muruganand Ashwath , Wadden Jack , Babila Clarissa May , Cantor Evan , Tunkle Leo , Wierzbicki Kyle , Stallard Stefanie , Dickson Robert P. , Wolfe Ian , Mody Rajen , Schwartz Jonathan , Franson Andrea , Robertson Patricia L. , Muraszko Karin M. , Maher Cormac O. , Garton Hugh J.L. , Qin Tingtin , Koschmann Carl
Published: April 2023

Nanopore Sensitivity/Specificity details
Supplementary Data from Electronic DNA Analysis of CSF Cell-free Tumor DNA to Quantify Multi-gene Molecular Response in Pediatric High-grade Glioma
Authors: Bruzek Amy K. , Ravi Karthik , Muruganand Ashwath , Wadden Jack , Babila Clarissa May , Cantor Evan , Tunkle Leo , Wierzbicki Kyle , Stallard Stefanie , Dickson Robert P. , Wolfe Ian , Mody Rajen , Schwartz Jonathan , Franson Andrea , Robertson Patricia L. , Muraszko Karin M. , Maher Cormac O. , Garton Hugh J.L. , Qin Tingtin , Koschmann Carl
Published: April 2023

All supplementary data except table S3A and S3B
Figure S2 from PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Authors: Guarneri Valentina , Dieci Maria Vittoria , Bisagni Giancarlo , Brandes Alba A. , Frassoldati Antonio , Cavanna Luigi , Musolino Antonino , Giotta Francesco , Rimanti Anita , Garrone Ornella , Bertone Elena , Cagossi Katia , Nanni Oriana , Piacentini Federico , Orvieto Enrico , Griguolo Gaia , Curtarello Matteo , Urso Loredana , Paré Laia , Chic Nuria , D'Amico Roberto , Prat Aleix , Conte Pierfranco
Published: April 2023

Pattern of PIK3CA mutations in the ShortHER trial (n=803 patients).
Supplementary Figures and Tables from B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade
Authors: Kim Sangwoo S. , Shen Sarek , Miyauchi Sayuri , Sanders P. Dominick , Franiak-Pietryga Ida , Mell Loren , Gutkind J. Silvio , Cohen Ezra E.W. , Califano Joseph A. , Sharabi Andrew B.
Published: April 2023

Supplementary Figures 1-11 and Supplementary Tables 1-11
Figure S4 from Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors
Authors: Glisson Bonnie S. , Leidner Rom S. , Ferris Robert L. , Powderly John , Rizvi Naiyer A. , Keam Bhumsuk , Schneider Reva , Goel Sanjay , Ohr James P. , Burton Jennifer , Zheng Yanan , Eck Steven , Gribbin Matthew , Streicher Katie , Townsley Danielle M. , Patel Sandip Pravin
Published: April 2023

Figure S4: Changes in the intratumoral immune phenotype
Supplementary Data from Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M–positive Non–Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study
Authors: Xing Ligang , Pan Yueyin , Shi Yuankai , Shu Yongqian , Feng Jifeng , Li Wei , Cao Lejie , Wang Lifeng , Gu Wei , Song Yong , Xing Puyuan , Liu Yutao , Gao Wen , Cui Jiuwei , Hu Nana , Li Rutian , Bao Hua , Shao Yang , Yu Jinming
Published: April 2023

Supplementary Figure 1
Supplementary Legends from Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer
Authors: Cooper Alissa J. , Kobayashi Yoshihisa , Kim Dewey , Clifford Sarah E. , Kravets Sasha , Dahlberg Suzanne E. , Chambers Emily S. , Li Jiaqi , Rangachari Deepa , Nguyen Tom , Costa Daniel B. , Rabin Michael S. , Wagle Nikhil , Sholl Lynette M. , Jänne Pasi A , Oxnard Geoffrey R.
Published: April 2023

Supplementary Legends
Figure S1: CONSORT diagram. from Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer
Authors: Cooper Alissa J. , Kobayashi Yoshihisa , Kim Dewey , Clifford Sarah E. , Kravets Sasha , Dahlberg Suzanne E. , Chambers Emily S. , Li Jiaqi , Rangachari Deepa , Nguyen Tom , Costa Daniel B. , Rabin Michael S. , Wagle Nikhil , Sholl Lynette M. , Jänne Pasi A , Oxnard Geoffrey R.
Published: April 2023

Thirteen patients were enrolled and underwent at least one cycle of therapy.
Supplementary Data from AsiDNA Is a Radiosensitizer with no Added Toxicity in Medulloblastoma Pediatric Models
Authors: Ferreira Sofia , Foray Chloe , Gatto Alberto , Larcher Magalie , Heinrich Sophie , Lupu Mihaela , Mispelter Joel , Boussin François D. , Pouponnot Célio , Dutreix Marie
Published: April 2023

Legends for supplementary data
FigureS3 from AsiDNA Is a Radiosensitizer with no Added Toxicity in Medulloblastoma Pediatric Models
Authors: Ferreira Sofia , Foray Chloe , Gatto Alberto , Larcher Magalie , Heinrich Sophie , Lupu Mihaela , Mispelter Joel , Boussin François D. , Pouponnot Célio , Dutreix Marie
Published: April 2023

Effect of the combination of treatments in preclinical high-risk HDMB03 models.
Protocol from Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial
Authors: Mei Qian , Zhang Wenying , Liu Yang , Yang Qingming , Rasko John E.J. , Nie Jing , Liu Jiejie , Li Xiang , Dong Liang , Chen Meixia , Zhang Yan , Shi Lu , Wu Huitao , Han Weidong
Published: April 2023

Protocol of clinical trial
Figure S5 from Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial
Authors: Mei Qian , Zhang Wenying , Liu Yang , Yang Qingming , Rasko John E.J. , Nie Jing , Liu Jiejie , Li Xiang , Dong Liang , Chen Meixia , Zhang Yan , Shi Lu , Wu Huitao , Han Weidong
Published: April 2023

CT scans of the immunotherapy-related pneumonitis
Table S1 from Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis
Authors: Indraccolo Stefano , De Salvo Gian Luca , Verza Martina , Caccese Mario , Esposito Giovanni , Piga Ilaria , Del Bianco Paola , Pizzi Marco , Gardiman Marina Paola , Eoli Marica , Rudà Roberta , Brandes Alba Ariela , Ibrahim Toni , Rizzato Simona , Lolli Ivan , Zagonel Vittorina , Lombardi Giuseppe
Published: April 2023

Digital pathology raw data
Figure S1 from Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial
Authors: Mei Qian , Zhang Wenying , Liu Yang , Yang Qingming , Rasko John E.J. , Nie Jing , Liu Jiejie , Li Xiang , Dong Liang , Chen Meixia , Zhang Yan , Shi Lu , Wu Huitao , Han Weidong
Published: April 2023

Spider plots of responses in patients
Supplemental Figure 1 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer
Authors: Dunphy Mark P.S. , Pressl Christina , Pillarsetty Nagavarakishore , Grkovski Milan , Modi Shanu , Jhaveri Komal , Norton Larry , Beattie Bradley J. , Zanzonico Pat B. , Zatorska Danuta , Taldone Tony , Ochiana Stefan O. , Uddin Mohammad M. , Burnazi Eva M. , Lyashchenko Serge K. , Hudis Clifford A. , Bromberg Jacqueline , Schöder Heiko M. , Fox Josef J. , Zhang Hanwen , Chiosis Gabriela , Lewis Jason S. , Larson Steven M.
Published: April 2023

Supplemental Figure 1. Tumor retention of PU-H71 tracer varied considerably between patients. Tumor retention expressed as tumor:bloodpool SUV ratio (y-axis) measured on PET at 4 and 24 hours post tracer-injection.
Supplementary Fig 4 from Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2− Advanced Breast Cancer
Authors: Bardia Aditya , Modi Shanu , Oliveira Mafalda , Cortes Javier , Campone Mario , Ma Brigette , Dirix Luc , Weise Amy , Hewes Becker , Diaz-Padilla Ivan , Han Yu , Deshpande Priya , Samant Tanay S. , Lorenc Karen Rodriguez , He Wei , Su Fei , Chavez-MacGregor Mariana
Published: April 2023

Supplementary Fig 4
Supplementary Fig 3 from Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2− Advanced Breast Cancer
Authors: Bardia Aditya , Modi Shanu , Oliveira Mafalda , Cortes Javier , Campone Mario , Ma Brigette , Dirix Luc , Weise Amy , Hewes Becker , Diaz-Padilla Ivan , Han Yu , Deshpande Priya , Samant Tanay S. , Lorenc Karen Rodriguez , He Wei , Su Fei , Chavez-MacGregor Mariana
Published: April 2023

Supplementary Fig 3
Supplementary Figure from Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors
Authors: Lee Jenny H. , Menzies Alexander M. , Carlino Matteo S. , McEvoy Ashleigh C. , Sandhu Shahneen , Weppler Alison M. , Diefenbach Russell J. , Dawson Sarah-Jane , Kefford Richard F. , Millward Michael J. , Al-Ogaili Zeyad , Tra Thien , Gray Elin S. , Wong Stephen Q. , Scolyer Richard A. , Long Georgina V. , Rizos Helen
Published: April 2023

Supplementary Figure 1. Flow chart of patient selection. Supplementary Figure 2. Flowchart of patients with disease response assessment available (n = 57).
Table S2 from Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study
Authors: Bagley Stephen J. , Nabavizadeh S. Ali , Mays Jazmine J. , Till Jacob E. , Ware Jeffrey B. , Levy Scott , Sarchiapone Whitney , Hussain Jasmin , Prior Timothy , Guiry Samantha , Christensen Theresa , Yee Stephanie S. , Nasrallah MacLean P. , Morrissette Jennifer J.D. , Binder Zev A. , O'Rourke Donald M. , Cucchiara Andrew J. , Brem Steven , Desai Arati S. , Carpenter Erica L.
Published: April 2023

Tissue fusion transcript panel gene coverage (55 genes)
Supplementary Figure S3 from Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer
Authors: Kang Yoon-Koo , Bang Yung-Jue , Kondo Shunsuke , Chung Hyun Cheol , Muro Kei , Dussault Isabelle , Helwig Christoph , Osada Motonobu , Doi Toshihiko
Published: April 2023

Supplementary Figure S3 shows immune phenotypes by IRC-assessed response.
Supplementary Figure 1 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Authors: Ladomersky Erik , Zhai Lijie , Lauing Kristen L. , Bell April , Xu Jiahui , Kocherginsky Masha , Zhang Bin , Wu Jennifer D. , Podojil Joseph R. , Platanias Leonidas C. , Mochizuki Aaron Y. , Prins Robert M. , Kumthekar Priya , Raizer Jeffrey J. , Dixit Karan , Lukas Rimas V. , Horbinski Craig , Wei Min , Zhou Changyou , Pawelec Graham , Campisi Judith , Grohmann Ursula , Prendergast George C. , Munn David H. , Wainwright Derek A.
Published: April 2023

Supplemental Figure 1. Inclusion and exclusion criteria for the analysis of human subjects diagnosed with glioblastoma (GBM).
TMK1_2 from Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer
Authors: Galletti Giuseppe , Zhang Chao , Gjyrezi Ada , Cleveland Kyle , Zhang Jiaren , Powell Sarah , Thakkar Prashant V. , Betel Doron , Shah Manish A. , Giannakakou Paraskevi
Published: April 2023

TMK1_2 from Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer
Figure S2 from Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy
Authors: Zhou Katherine I. , Peterson Bryan , Serritella Anthony , Thomas Joseph , Reizine Natalie , Moya Stephanie , Tan Carol , Wang Yan , Catenacci Daniel V.T.
Published: April 2023

Supplementary Figure S2. Comparison of PD-L1 expression and TMB in primary vs. metastatic tumors, excluding MSI-H tumors.
Figure S1 from Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy
Authors: Zhou Katherine I. , Peterson Bryan , Serritella Anthony , Thomas Joseph , Reizine Natalie , Moya Stephanie , Tan Carol , Wang Yan , Catenacci Daniel V.T.
Published: April 2023

Supplementary Figure S1. Relationship between PD-L1-status, MSI-status, and TMB-level.
HS746T_2 from Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer
Authors: Galletti Giuseppe , Zhang Chao , Gjyrezi Ada , Cleveland Kyle , Zhang Jiaren , Powell Sarah , Thakkar Prashant V. , Betel Doron , Shah Manish A. , Giannakakou Paraskevi
Published: April 2023

HS746T_2 from Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer
Supplementary Data from Discovery of Berberine that Targetedly Induces Autophagic Degradation of both BCR-ABL and BCR-ABL T315I through Recruiting LRSAM1 for Overcoming Imatinib Resistance
Authors: Yin Zhao , Huang Guiping , Gu Chunming , Liu Yanjun , Yang Juhua , Fei Jia
Published: April 2023

Supplementary Material
Supplementary Data from FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes
Authors: Sengal Asmerom T. , Patch Ann-Marie , Snell Cameron E. , Smith Deborah S. , Leung Samuel C.Y. , Talhouk Aline , Williams Elizabeth D. , McAlpine Jessica N. , Pollock Pamela M.
Published: April 2023

Supplementary Figures 1_6
Supplementary Data from FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes
Authors: Sengal Asmerom T. , Patch Ann-Marie , Snell Cameron E. , Smith Deborah S. , Leung Samuel C.Y. , Talhouk Aline , Williams Elizabeth D. , McAlpine Jessica N. , Pollock Pamela M.
Published: April 2023

Supplementary Tables 1-6
Supplementary Materials and Methods from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Authors: Jin Zhao-Hui , Tsuji Atsushi B. , Degardin Mélissa , Sugyo Aya , Obara Satoshi , Wakizaka Hidekatsu , Nagatsu Kotaro , Hu Kuan , Zhang Ming-Rong , Dumy Pascal , Boturyn Didier , Higashi Tatsuya
Published: April 2023

Supplementary Materials and Methods for integrin expression analysis, autoradiography, ITD of Cy5.5-RaftRGD in relation to the tumor microenvironment (in s.c. tumors), PET/CT or PET/CECT imaging and quantification, Ki-67 immunostaining, TUNEL assay, and quantification, survival study, and toxicity evaluation.
Figure S4 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Authors: Jin Zhao-Hui , Tsuji Atsushi B. , Degardin Mélissa , Sugyo Aya , Obara Satoshi , Wakizaka Hidekatsu , Nagatsu Kotaro , Hu Kuan , Zhang Ming-Rong , Dumy Pascal , Boturyn Didier , Higashi Tatsuya
Published: April 2023

Spatial relationship of intratumoral Cy5.5-RaftRGD to the tumor microenvironment (magnified images)
Figure S2 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Authors: Jin Zhao-Hui , Tsuji Atsushi B. , Degardin Mélissa , Sugyo Aya , Obara Satoshi , Wakizaka Hidekatsu , Nagatsu Kotaro , Hu Kuan , Zhang Ming-Rong , Dumy Pascal , Boturyn Didier , Higashi Tatsuya
Published: April 2023

Integrin expression in OVCAR-3 and IGR-OV1 s.c. xenografts
Figure S16 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Authors: Jin Zhao-Hui , Tsuji Atsushi B. , Degardin Mélissa , Sugyo Aya , Obara Satoshi , Wakizaka Hidekatsu , Nagatsu Kotaro , Hu Kuan , Zhang Ming-Rong , Dumy Pascal , Boturyn Didier , Higashi Tatsuya
Published: April 2023

64Cu-RaftRGD-based TRT (toxicity evaluation: hepatorenal functions and gastrointestinal state)
Supplementary fig 14 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Supplementary Figure 14: Differentially expressed genes by cluster in whole blood single cell RNA sequencing.
Figure S15 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Authors: Jin Zhao-Hui , Tsuji Atsushi B. , Degardin Mélissa , Sugyo Aya , Obara Satoshi , Wakizaka Hidekatsu , Nagatsu Kotaro , Hu Kuan , Zhang Ming-Rong , Dumy Pascal , Boturyn Didier , Higashi Tatsuya
Published: April 2023

64Cu-RaftRGD-based TRT (toxicity evaluation: body weight and hematology)
Figure S12 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Authors: Jin Zhao-Hui , Tsuji Atsushi B. , Degardin Mélissa , Sugyo Aya , Obara Satoshi , Wakizaka Hidekatsu , Nagatsu Kotaro , Hu Kuan , Zhang Ming-Rong , Dumy Pascal , Boturyn Didier , Higashi Tatsuya
Published: April 2023

Correlation between tumor length (mm) and tumor weight (g)
Supplementary Legends from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Supplementary Legends
Supplementary Data from Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors
Authors: Varghese Anna M. , Cardin Dana B. , Hersch Jonathan , Benson Al B. , Hochster Howard S. , Makris Lukas , Hamada Kensuke , Berlin Jordan D. , Saltz Leonard B.
Published: April 2023

Supplementary methods, supplementary results and Supplementary Tables S1 and S2
Supplementary Data from Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer
Authors: Datta Jashodeep , Smith J. Joshua , Chatila Walid K. , McAuliffe John C. , Kandoth Cyriac , Vakiani Efsevia , Frankel Timothy L. , Ganesh Karuna , Wasserman Isaac , Lipsyc-Sharf Marla , Guillem Jose , Nash Garrett M. , Paty Philip B. , Weiser Martin R. , Saltz Leonard B. , Berger Michael F. , Jarnagin William R. , Balachandran Vinod , Kingham T. Peter , Kemeny Nancy E. , Cercek Andrea , Garcia-Aguilar Julio , Taylor Barry S. , Viale Agnes , Yaeger Rona , Solit David B. , Schultz Nikolaus , D'Angelica Michael I.
Published: April 2023

Supplementary Methods, References, and Figures
Supplementary Figure S5 from Preclinical Activity of SAR408701: A Novel Anti-CEACAM5–maytansinoid Antibody–drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors
Authors: Decary Stéphanie , Berne Pierre-François , Nicolazzi Céline , Lefebvre Anne-Marie , Dabdoubi Tarik , Cameron Béatrice , Rival Pierrick , Devaud Catherine , Prades Catherine , Bouchard Hervé , Cassé Alhassan , Henry Christophe , Amara Céline , Brillac Claire , Ferrari Paul , Maçon Laetitia , Lacoste Eric , Combeau Cecile , Beys Eric , Naimi Souad , García-Echeverría Carlos , Mayaux Jean-François , Blanc Véronique
Published: April 2023

Supplementary Figure S5
Supplementary Figure S4 from Preclinical Activity of SAR408701: A Novel Anti-CEACAM5–maytansinoid Antibody–drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors
Authors: Decary Stéphanie , Berne Pierre-François , Nicolazzi Céline , Lefebvre Anne-Marie , Dabdoubi Tarik , Cameron Béatrice , Rival Pierrick , Devaud Catherine , Prades Catherine , Bouchard Hervé , Cassé Alhassan , Henry Christophe , Amara Céline , Brillac Claire , Ferrari Paul , Maçon Laetitia , Lacoste Eric , Combeau Cecile , Beys Eric , Naimi Souad , García-Echeverría Carlos , Mayaux Jean-François , Blanc Véronique
Published: April 2023

Supplementary Figure S4
Supplementary Figure S2 from Preclinical Activity of SAR408701: A Novel Anti-CEACAM5–maytansinoid Antibody–drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors
Authors: Decary Stéphanie , Berne Pierre-François , Nicolazzi Céline , Lefebvre Anne-Marie , Dabdoubi Tarik , Cameron Béatrice , Rival Pierrick , Devaud Catherine , Prades Catherine , Bouchard Hervé , Cassé Alhassan , Henry Christophe , Amara Céline , Brillac Claire , Ferrari Paul , Maçon Laetitia , Lacoste Eric , Combeau Cecile , Beys Eric , Naimi Souad , García-Echeverría Carlos , Mayaux Jean-François , Blanc Véronique
Published: April 2023

Supplementary Figure S2
Supplementary Table from EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
Authors: Lheureux Stephanie , Oaknin Ana , Garg Swati , Bruce Jeffrey P. , Madariaga Ainhoa , Dhani Neesha C. , Bowering Valerie , White Justin , Accardi Sarah , Tan Qian , Braunstein Marsela , Karakasis Katherine , Cirlan Iulia , Pedersen Stephanie , Li Tiantiam , Fariñas-Madrid Lorena , Lee Yeh Chen , Liu Zhihui (Amy) , Pugh Trevor J. , Oza Amit M.
Published: April 2023

Supplementary table
Table S1 from Model-based Dose Individualization of Sunitinib in Gastrointestinal Stromal Tumors
Authors: Centanni Maddalena , Krishnan Sreenath M. , Friberg Lena E.
Published: April 2023

Supplementary Table 1
Table S2 from Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition
Authors: Basler Lucas , Gabryś Hubert S. , Hogan Sabrina A. , Pavic Matea , Bogowicz Marta , Vuong Diem , Tanadini-Lang Stephanie , Förster Robert , Kudura Ken , Huellner Martin W. , Dummer Reinhard , Guckenberger Matthias , Levesque Mitchell P.
Published: April 2023

Summary of patient outcome of the individual groups (with landmark analysis) The landmark method was applied, that is all events before 5 months were excluded. 95% confidence intervals were provided in parentheses. PP-only patients were the best performing group, with a similar outcome compared to responding patients. TPD-only patients presented a significantly worse OS of 10 vs. 30 months in the PP-only group (p=0.002, FWER=0.010). Patients with mixed PP&TPD were in between both other groups.
Supplementary Tables from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy
Authors: El Sissy Carine , Kirilovsky Amos , Van den Eynde Marc , Muşină Ana-Maria , Anitei Maria-Gabriela , Romero Alfredo , Marliot Florence , Junca Audelaure , Doyen Jérôme , Mlecnik Bernhard , Haicheur Nacilla , Fredriksen Tessa , Lagorce Christine , Jouret-Mourin Anne , Leonard Daniel , Bibeau Frédéric , Iseas Soledad , Roca Enrique L. , Cabanne Ana M. , Vaccaro Carlos A. , Santino Juan P. , Huertas Eduardo , Tougeron David , Carvalho Carlos , Figueiredo Nuno , Perez Rodrigo O. , Habr-Gama Angelita , Scripcariu Viorel , Gerard Jean-Pierre , Galon Jérôme , Zeitoun Guy , Pagès Franck
Published: April 2023

Supplementary Tables
Supplementary Tables S1-S5 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Authors: Wei Hui , Wang Ying , Gale Robert Peter , Lin Dong , Zhou Chunlin , Liu Bingcheng , Qiu Shaowei , Gu Runxia , Li Yan , Zhao Xingli , Wei Shuning , Gong Benfa , Liu Kaiqi , Gong Xiaoyuan , Liu Yuntao , Zhang Guangji , Song Zhen , Wang Yang , Li Wei , Mi Yingchang , Wang Jianxiang
Published: April 2023

Supplementary Tables S1-S5
Figure S3 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Authors: Wei Hui , Wang Ying , Gale Robert Peter , Lin Dong , Zhou Chunlin , Liu Bingcheng , Qiu Shaowei , Gu Runxia , Li Yan , Zhao Xingli , Wei Shuning , Gong Benfa , Liu Kaiqi , Gong Xiaoyuan , Liu Yuntao , Zhang Guangji , Song Zhen , Wang Yang , Li Wei , Mi Yingchang , Wang Jianxiang
Published: April 2023

Figure S3. Outcomes after induction when censoring transplant recipients.
Supplementary Figure 8 from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Authors: Ryan Meagan B. , Fece de la Cruz Ferran , Phat Sarah , Myers David T. , Wong Edmond , Shahzade Heather A. , Hong Catriona B. , Corcoran Ryan B.
Published: April 2023

Supplementary Figure S8. KRASG12C and SHP2 inhibition does not inhibit the growth of signaling of a non-KRASG12C mutant cell line.
Supplementary Figure 7 from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Authors: Ryan Meagan B. , Fece de la Cruz Ferran , Phat Sarah , Myers David T. , Wong Edmond , Shahzade Heather A. , Hong Catriona B. , Corcoran Ryan B.
Published: April 2023

Supplementary Figure S7. SHP2 inhibition enhances the efficacy of KRASG12C inhibition.
Supplementary Figure 6 from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Authors: Ryan Meagan B. , Fece de la Cruz Ferran , Phat Sarah , Myers David T. , Wong Edmond , Shahzade Heather A. , Hong Catriona B. , Corcoran Ryan B.
Published: April 2023

Supplementary Figure S6. SHP2 inhibition enhances suppression of MAPK signaling in the presence of KRASG12C inhibition.
Supplementary Figure 5 from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Authors: Ryan Meagan B. , Fece de la Cruz Ferran , Phat Sarah , Myers David T. , Wong Edmond , Shahzade Heather A. , Hong Catriona B. , Corcoran Ryan B.
Published: April 2023

Supplementary Figure S5. Combined KRASG12C and SHP2 or MAPK inhibition improves in vitro efficacy
Supplementary Figure 3 from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Authors: Ryan Meagan B. , Fece de la Cruz Ferran , Phat Sarah , Myers David T. , Wong Edmond , Shahzade Heather A. , Hong Catriona B. , Corcoran Ryan B.
Published: April 2023

Supplementary Figure S3. RTK inhibitors display variable cooperative effects with KRASG12C inhibitors across models.
Supplementary Fig 2 from Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma
Authors: Paradis Justine S. , Acosta Monica , Saddawi-Konefka Robert , Kishore Ayush , Lubrano Simone , Gomes Frederico , Arang Nadia , Tiago Manoela , Coma Silvia , Wu Xingyu , Ford Kyle , Day Chi-Ping , Merlino Glenn , Mali Prashant , Pachter Jonathan A. , Sato Takami , Aplin Andrew E. , Gutkind J. Silvio
Published: April 2023

Supplementary figure S2. Isobologram analysis.